Charles River Labs’ spectacular announcement that it intends to acquire China’s most visible CRO, WuXi PharmaTech, has already drawn criticism over the price, $1.6 billion (see story). Now an analyst is making the case that another, perhaps more significant, roadblock exists that may derail the proposed transaction: approval of the deal from China’s government. More details...

Stock Symbols: (NYSE: CRL) (NYSE: WX)